379 related articles for article (PubMed ID: 27833586)
1. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.
Marzagalli M; Montagnani Marelli M; Casati L; Fontana F; Moretti RM; Limonta P
Front Endocrinol (Lausanne); 2016; 7():140. PubMed ID: 27833586
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines.
Marzagalli M; Casati L; Moretti RM; Montagnani Marelli M; Limonta P
PLoS One; 2015; 10(7):e0134396. PubMed ID: 26225426
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
4.
Muñoz-Couselo E; Adelantado EZ; Ortiz C; García JS; Perez-Garcia J
Onco Targets Ther; 2017; 10():3941-3947. PubMed ID: 28860801
[TBL] [Abstract][Full Text] [Related]
5.
Jenkins RW; Sullivan RJ
Melanoma Manag; 2016 Mar; 3(1):47-59. PubMed ID: 30190872
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
8. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element.
Kostelac D; Rechkemmer G; Briviba K
J Agric Food Chem; 2003 Dec; 51(26):7632-5. PubMed ID: 14664520
[TBL] [Abstract][Full Text] [Related]
9. Bioassays for estrogenic activity: development and validation of estrogen receptor (ERalpha/ERbeta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies.
Li J; Lee L; Gong Y; Shen P; Wong SP; Wise SD; Yong EL
Assay Drug Dev Technol; 2009 Feb; 7(1):80-9. PubMed ID: 19382890
[TBL] [Abstract][Full Text] [Related]
10. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
11. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells.
Mueller SO; Simon S; Chae K; Metzler M; Korach KS
Toxicol Sci; 2004 Jul; 80(1):14-25. PubMed ID: 15084758
[TBL] [Abstract][Full Text] [Related]
12. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.
Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G
J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
14. Hormonal regulation of estrogen receptor alpha and beta gene expression in human granulosa-luteal cells in vitro.
Chiang CH; Cheng KW; Igarashi S; Nathwani PS; Leung PC
J Clin Endocrinol Metab; 2000 Oct; 85(10):3828-39. PubMed ID: 11061546
[TBL] [Abstract][Full Text] [Related]
15. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
16. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells.
Zhou S; Turgeman G; Harris SE; Leitman DC; Komm BS; Bodine PV; Gazit D
Mol Endocrinol; 2003 Jan; 17(1):56-66. PubMed ID: 12511606
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells.
Dago DN; Scafoglio C; Rinaldi A; Memoli D; Giurato G; Nassa G; Ravo M; Rizzo F; Tarallo R; Weisz A
BMC Genomics; 2015 May; 16(1):367. PubMed ID: 25956916
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
